Sahin Ugur
Known title: Chief Executive OfficerCIK: 0002123975
Associated companies
Transaction History
| BNTX | ▼ Sell | Open Market | 36,209 | $3.5M | 10/9/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 27,000 | $2.5M | 10/8/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 24,000 | $2.3M | 10/7/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 21,000 | $2.0M | 10/6/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 72,000 | $7.0M | 10/5/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 17,000 | $1.6M | 10/2/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 17,000 | $1.7M | 10/1/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 32,000 | $3.1M | 9/30/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 34,000 | $3.3M | 9/29/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 34,000 | $3.3M | 9/28/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 27,000 | $2.7M | 9/25/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 39,000 | $3.9M | 9/24/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 30,000 | $3.0M | 9/23/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 46,000 | $4.6M | 9/22/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 33,000 | $3.2M | 9/21/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 30,000 | $2.9M | 9/18/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 34,000 | $3.4M | 9/17/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 15,000 | $1.4M | 9/16/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 34,000 | $3.3M | 9/15/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 41,000 | $4.1M | 9/14/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 45,000 | $4.4M | 9/11/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 20,500 | $2.0M | 9/10/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 36,000 | $3.5M | 9/9/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 37,000 | $3.7M | 9/8/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 31,500 | $3.3M | 9/4/2026 | View on chart |
| BNTX | ▼ Sell | Open Market | 45,000 | $4.6M | 9/3/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BioNTech shares slip after cancer trial misses PFS endpoint
BioNTech's shares fell about 7% after a late‑stage mRNA cancer vaccine trial did not meet its primary progression‑free survival goal. The miss has prompted analysts to reassess the company's oncology pipeline and contributed to a broader pullback in the stock. Canaccord Genuity kept its rating but lowered its price target to $132, reflecting the recent results. The stock is trading near a support level around $90.86 and its RSI is in the lower‑mid range.
BioNTech shares slip after cancer trial misses PFS endpoint. BioNTech's shares fell about 7% after a late‑stage mRNA cancer vaccine trial did not meet its primary progression‑free survival goal. The miss has prompted analysts to reassess the company's oncology pipeline and contributed to a broader pullback in the stock. Canaccord Genuity kept its rating but lowered its price target to $132, reflecting the recent results. The stock is trading near a support level around $90.86 and its RSI is in the lower‑mid range.